No Data
No Data
Syntis Bio Launches to Revolutionize Oral Therapy for Obesity, Diabetes and Rare Diseases by Unlocking the Full Therapeutic Potential of the Small Intestine
Lead program SYNT-101 now in human trials to validate potential as a once-daily oral obesity therapyOrphan pediatric portfolio acquired from Codexis expands pipeline with first-in-class oral enzyme re
Codexis Initiated at Overweight by Cantor Fitzgerald
Codexis Initiated at Overweight by Cantor Fitzgerald
Cantor Fitzgerald Starts Codexis With Overweight Rating, $11 Price Target
Codexis (CDXS) has an average rating of buy and price targets ranging from $3 to $11, according to analysts polled by Capital IQ. Price: 3.3473, Change: +0.16, Percent Change: +4.93
Codexis to Participate in Jefferies Global Healthcare Conference
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the Company will attend the Jefferies Global Healthcare Conference, being held
Codexis to Participate in TD Cowen 2nd Annual Sustainability Week
REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the Company will participate in a panel discussion titled, "Sustainable API
Stifel Nicolaus Reaffirms Their Buy Rating on Codexis (CDXS)
loading...
loading...
No Data